Anna Becker
Clinical Psychopharmacologist and Clinical Researcher
Data updated
Research Footprint
Anna Becker appears in 19 tracked papers (2021–2026), most studied alongside LSD, Psilocybin and Mescaline, across Healthy Volunteers, Medicinal Chemistry & Drug Development and Anxiety Disorders.
Most-cited paper: Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects (218 citations).
Frequent co-authors: Matthias Liechti, Friederike Holze and Lukas Ley.
Background & Research
Anna Becker is a clinical psychopharmacologist whose recent work has focused on rigorous, experimental human pharmacology studies of classic and novel psychedelics. She has been a key investigator on multiple randomized, double-blind, placebo-controlled, cross-over Phase I studies in healthy volunteers that examine acute subjective and physiological effects, safety profiles and pharmacokinetics of compounds including psilocybin, LSD, mescaline, intravenous DMT and MDMA–LSD co-administration. Becker’s research frequently addresses clinically important questions such as the influence of selective serotonin reuptake inhibitors on psychedelic response and the comparative acute profiles of different serotonergic hallucinogens.
Key Impact
Notable for leading early-phase, placebo-controlled human trials that characterise the acute effects, safety and pharmacokinetics of classic and novel psychedelics and for investigating interactions with serotonergic antidepressants.
Collaboration Network
26 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Anna Becker is associated with.